Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.

Circulation - 27 Oct 2015

Bergeron Nathalie, Phan Binh An P, Ding Yunchen, Fong Aleyna, Krauss Ronald M

Abstract excerpt

Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays an important role in the regulation of cholesterol homeostasis. By binding to hepatic low-density lipoprotein (LDL) receptors and promoting their lysosomal degradation, PCSK9 reduces LDL uptake, leading to an increase in LDL cholesterol concentrations. Gain-of-function mutations in PCSK9 associated with high LDL cholesterol and premature cardiovascular...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adipocytes
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to Hyperlipoproteinemias

Share to Oligonucleotides, Antisense

Share to Proprotein Convertase 9

Share to Proprotein Convertases

Share to Receptors, LDL

Source

Identifiers

PMID: 26503748
DOI: 10.1161/CIRCULATIONAHA.115.016080

Genes

PCSK9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.PMID 26503748Read ↗

Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.Semantic proximity Read ↗

The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors.Semantic proximity Read ↗

PCSK9: a key modulator of cardiovascular health.Semantic proximity Read ↗

The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications.Semantic proximity Read ↗

Targeting PCSK9 for the treatment of hypercholesterolemia.Semantic proximity Read ↗

Proprotein convertase subtilisin/kexin type 9 (PCSK9): lessons learned from patients with hypercholesterolemia.Semantic proximity Read ↗

PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future.Semantic proximity Read ↗

Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition.Semantic proximity Read ↗

PCSK9 inhibitors: the next frontier in low-density lipoprotein lowering.Semantic proximity Read ↗

PCSK9 Inhibitors: Pharmacology and Therapeutic PotentialSemantic proximity Read ↗

The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol.Semantic proximity Read ↗

Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.